LLY · News · 20261113N

Regulatory Approval - Orforglipron

ELI LILLY & Co · 2026-11-13 · Importance 53 · Surprise 60

China's National Medical Products Administration approved Eli Lilly's weight-loss pill orforglipron, marketed as Foundayo. The approval makes it the first oral GLP-1 treatment for obesity available in China and permits Lilly to enter the country's weight-management market. The news digest also reports that Lilly had committed $3 billion to expand manufacturing in China to support oral GLP-1 supply.

Key facts